Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

2012 ◽  
Vol 14 (12) ◽  
pp. 1145-1154 ◽  
Author(s):  
A. H. Barnett ◽  
S. Patel ◽  
R. Harper ◽  
R. Toorawa ◽  
S. Thiemann ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Phase Iii ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Double Blind Placebo ◽  
Diabetes Patients

scholarly journals Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia ◽  
2016 ◽  
Vol 59 (7) ◽  
pp. 1412-1421 ◽  
Author(s):  
Lennart Tonneijck ◽  
Mark M. Smits ◽  
Marcel H. A. Muskiet ◽  
Trynke Hoekstra ◽  
Mark H. H. Kramer ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Double Blind ◽  
Renal Effects ◽  
Double Blind Placebo ◽  
Diabetes Patients

scholarly journals A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Huub J. van Eyk ◽  
Elisabeth H. M. Paiman ◽  
Maurice B. Bizino ◽  
Paul de Heer ◽  
Petronella H. Geelhoed-Duijvestijn ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
South Asian ◽  
Randomised Trial ◽  
Ectopic Fat ◽  
Double Blind ◽  
Fat Accumulation ◽  
Double Blind Placebo ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document